Suppr超能文献

青光眼治疗中的视网膜神经节细胞替代:一项叙述性综述。

Retinal Ganglion Cell Replacement in Glaucoma Therapy: A Narrative Review.

作者信息

Kosior-Jarecka Ewa, Grzybowski Andrzej

机构信息

Department of Diagnostics and Microsurgery of Glaucoma, Medical University of Lublin, 20-079 Lublin, Poland.

Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, 60-836 Poznan, Poland.

出版信息

J Clin Med. 2024 Nov 27;13(23):7204. doi: 10.3390/jcm13237204.

Abstract

Glaucoma is a leading cause of irreversible blindness worldwide. It leads to the progressive degeneration of retinal ganglion cells (RGCs), the axons of which form the optic nerve. Enormous RGC apoptosis causes a lack of transfer of visual information to the brain. The RGC loss typical of the central nervous system is irreversible, and when glaucoma progresses, the total amount of RGCs in the retina enormously diminishes. The successful treatment in glaucoma patients is a direct neuroprotection by decreasing the intraocular pressure, which enables RGC protection but does not revive the lost ones. The intriguing new therapy for advanced glaucoma is the possibility of RGC replacement with new healthy cells. In this review article, the strategies regarding RGC replacement therapy are presented with the latest advances in the technique and the obstacles that it meets.

摘要

青光眼是全球不可逆性失明的主要原因。它会导致视网膜神经节细胞(RGCs)逐渐退化,其轴突形成视神经。大量的RGC凋亡导致视觉信息向大脑传递缺失。中枢神经系统典型的RGC损失是不可逆的,并且当青光眼进展时,视网膜中RGC的总量会大幅减少。青光眼患者的成功治疗是通过降低眼压进行直接神经保护,这能够保护RGC,但无法使已损失的RGC恢复。针对晚期青光眼的有趣新疗法是用新的健康细胞替代RGC的可能性。在这篇综述文章中,介绍了关于RGC替代疗法的策略、该技术的最新进展及其遇到的障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92f6/11642712/b4afa8e69bac/jcm-13-07204-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验